Owner's Briefing

The financial pressure on independent pharmacies has reached a structural breaking point. Direct and Indirect Remuneration (DIR) fees — retroactive clawbacks imposed by PBMs on dispensing revenue — totaled an estimated $12.6 billion across the industry in 2025, with independent pharmacies absorbing a disproportionate share relative to their dispensing volume. The perversity of the system is not lost on anyone who's read a reconciliation statement: pharmacies often don't know the true margin of a dispensed drug until months after the transaction, when the clawback is applied. Operating a profitable pharmacy under this system requires either significant scale or a deliberate strategy to diversify revenue beyond PBM-adjudicated dispensing.

The independents surviving this environment — and in some cases growing — are building a revenue stack that PBMs don't touch. Clinical services are the most significant opportunity: pharmacist-administered vaccines, point-of-care testing (A1C, cholesterol, COVID, flu), smoking cessation programs, diabetes management consultations, and medication therapy management (MTM) sessions all generate direct patient revenue or fee-for-service reimbursement that bypasses the PBM layer entirely. Pharmacies that have built clinical service revenue to 15%+ of total revenue report materially more stable margins than those that remain 90%+ dependent on dispensing.

The underutilized opportunity is compounding. Pharmacies with a USP 795 (non-sterile) compounding capability can fill a market gap that chain pharmacies and mail-order services cannot: customized medications for specific patient needs, particularly in veterinary compounding, hormone therapy, and pediatric formulations. Compounding margins are 60–80% — compared to 1–5% on many brand name PBM claims — and the market is undersupplied in most secondary markets. Certification and equipment represent a real upfront investment; the payback period for a well-run compounding operation is typically 14–18 months.